在PD-(L) 1抑制剂试验中的统计噪声:解开持久响应效应
Michael Coory1, Susan J Jordan2
1Mater Research Institute, The University of Queensland, Level 3, Aubigny Place, South Brisbane, Queensland, Australia.
Journal of clinical epidemiology
|November 6, 2024
概括
在对编程死亡-1/灵丹-1 抑制剂的癌症试验中,一小部分持久反应者可能解释不一致的结果. 这些患者可能会造成统计噪音,导致试验结果不可靠,并可能误解治疗效果.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
背景情况:
- 编程死亡-1/联结-1抑制剂 (PD-1/L1is) 是具有二分化的反应模式的关键癌症治疗方法.
- 一小部分患者 (5%-20%) 获得了持久的反应,而大多数患者的益处有限.
- 在不同的PD-1/L1抑制剂和癌症类型中观察到不一致的疗效结果,缺乏明确的解释.
研究的目的:
- 调查"持久反应者效应"作为PD-(L) 1i随机对照试验 (RCT) 中可变结果的潜在原因.
- 评估一组未确定的持久响应者如何引入统计噪音并影响试验功率和结果.
主要方法:
- 使用模拟来建模PD-(L) 1iRCT,将参与者分为持久响应者和适度响应者.
- 复制预先规定的场景5万次,可变的持久响应百分比 (5%-20%) 和适度响应者的整体生存危险比率 (HR) (0.8-1.0).
- 评估了持久响应者对统计能力,治疗效果估计和误导性危害信号的可能性的影响.
主要成果:
- 当适度响应者治疗效果最小时,统计能力保持在80%以下,这阻碍了对持久响应者的可靠检测.
- 对统计学上显著的结果存在显著的概率,这些结果偶然高估了治疗效应.
- 在5%的持久响应者中,有7.2%的概率显示统计学上显著的试验平均HR{}OS为0.77,而HR{}OS超过1.0的概率为20%,表明假伤害.
结论:
- 未识别的持久响应者可以模仿低功率研究的特征,包括假负结果和不可复制的益处估计.
- 这种现象为PD-L1iRCT中令人费解的不一致的发现提供了合理的解释.
- 对患者分层和先进分析方法的进一步研究可能会改善PD-L1i试验数据的解释.
相关概念视频
Parkinson's Disease: Treatment
224
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
224
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
87
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
87
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Desensitization and Tachyphylaxis
1.5K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
1.5K
Censoring Survival Data
65
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
65


